The estimated Net Worth of Badri N Dasu is at least 1.02 百万$ dollars as of 28 February 2019. Mr. Dasu owns over 9,206 units of Acelrx Pharmaceuticals Inc stock worth over 97,410$ and over the last 14 years he sold ACRX stock worth over 141,755$. In addition, he makes 776,258$ as Chief Engineering Officer at Acelrx Pharmaceuticals Inc.
Badri has made over 3 trades of the Acelrx Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 9,206 units of ACRX stock worth 25,869$ on 28 February 2019.
The largest trade he's ever made was exercising 37,500 units of Acelrx Pharmaceuticals Inc stock on 19 October 2017 worth over 45,000$. On average, Badri trades about 2,421 units every 16 days since 2011. As of 28 February 2019 he still owns at least 113,267 units of Acelrx Pharmaceuticals Inc stock.
You can see the complete history of Mr. Dasu stock trades at the bottom of the page.
Badri N. Dasu serves as Chief Engineering Officer of the Company. He has served as our Chief Engineering Officer since September 2007. From December 2005 until September 2007, Mr. Dasu served as Vice President of Medical Device Engineering at Anesiva, Inc., a biopharmaceutical company. From March 2002 until December 2005, Mr. Dasu served as Vice President for Manufacturing and Device Development at AlgoRx Pharmaceuticals, Inc., an emerging pain management company, which merged with Corgentech Inc., a biotechnology company, in December 2005. From January 2000 until March 2002, Mr. Dasu served as Vice President of Manufacturing and Process Development at PowderJect Pharmaceuticals, a vaccine, drug and diagnostics delivery company that was acquired by Chiron Corporation in 2003 and later acquired by Novartis AG, a global healthcare and pharmaceutical company, in 2006. Previously, Mr. Dasu served in various capacities in process development at Metrika, Inc., a company focused on the manufacture and marketing of disposable diabetes monitoring products that was acquired by Bayer HealthCare, LLC in 2006, and at Cygnus, Inc., a drug delivery and specialty pharmaceuticals company. Mr. Dasu holds a B.E. in Chemical Engineering from the University of Mangalore, India and a M.S. in Chemical Engineering from the University of Tulsa.
As the Chief Engineering Officer of Acelrx Pharmaceuticals Inc, the total compensation of Badri Dasu at Acelrx Pharmaceuticals Inc is 776,258$. There are 4 executives at Acelrx Pharmaceuticals Inc getting paid more, with Vincent Angotti having the highest compensation of 2,125,050$.
Badri Dasu is 57, he's been the Chief Engineering Officer of Acelrx Pharmaceuticals Inc since 2007. There are 8 older and 5 younger executives at Acelrx Pharmaceuticals Inc. The oldest executive at Acelrx Pharmaceuticals Inc is Lawrence G. Hamel, 69, who is the Consultant.
Badri's mailing address filed with the SEC is C/O ACELRX PHARMACEUTICALS, INC., 25821 INDUSTRIAL BLVD., SUITE 400, HAYWARD, CA, 94545.
Over the last 14 years, insiders at Acelrx Pharmaceuticals Inc have traded over 25,363,406$ worth of Acelrx Pharmaceuticals Inc stock and bought 5,245,025 units worth 26,783,172$ . The most active insiders traders include Advisors Llcperceptive Life...、Advisors Llcedelman Josephp...、Mark Ajaeger Wilfred Ethree.... On average, Acelrx Pharmaceuticals Inc executives and independent directors trade stock every 63 days with the average trade being worth of 109,939$. The most recent stock trade was executed by Vincent J. Angotti on 13 December 2023, trading 10,000 units of ACRX stock currently worth 7,300$.
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Acelrx Pharmaceuticals Inc executives and other stock owners filed with the SEC include: